Tiziana Life Sciences plc ("Tiziana" or the "Company") Gabriele Cerrone, Chairman of Tiziana Life Sciences, to give interview on Bloomberg Television US at 1:20 PM ET Today NEW YORK and LONDON - 29 March 2021 - Tiziana L

Tiziana Life Sciences plc

("Tiziana" or the "Company")

Gabriele Cerrone, Chairman of Tiziana

Life Sciences, to give interview on Bloomberg Television US at 1:20 PM ET Today

NEW YORK and LONDON - 29 March 2021 -

Tiziana Life Sciences. (NASDAQ: TLSA; LSE: TILS), a biotechnology company focused on innovative therapeutics for oncology,

inflammation, and infectious diseases, announces that the Chairman and Founder, Gabriele Cerrone, will give an interview on

Bloomberg Television on Monday 29 March 2021 at 1.20 p.m. US Eastern Standard Time (6.20 p.m. London) as part of the

Bloomberg Surveillance Show.

About Tiziana Life Sciences

Tiziana Life Sciences plc is a UK biotechnology

company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology. In

addition to Milciclib, the Company is also developing Foralumab for liver diseases. Foralumab is the only fully human anti-CD3

monoclonal antibody in clinical development in the world. This Phase 2 compound has potential application in a wide range of autoimmune

and inflammatory diseases, such as nonalcoholic steatohepatitis (NASH), ulcerative colitis, multiple sclerosis, type-1 diabetes

(T1D), Crohn's disease, psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. The company is

accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced

inflammation, especially for treatment of COVID-19 patients.

For further enquiries:

United Kingdom Investors:

Tiziana Life Sciences plc (TLSA)

Gabriele Cerrone, Chairman and founder

U.S. Investor Relations Contact:

RedChip Companies, Inc.

Dave Gentry1-800 RED-CHIP (733-2447)